AACR

13 kwietnia 2022

American Association for Cancer Research (AACR) Annual Meeting, April 8-13, 2022

Rok

2022

Cel

RVU120 (CDK8/CDK19), RVU 305 (PRMT5)

Zasoby na tej stronie

Pobierz zasoby

  • plik pdf

    "RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo"

    Pobierz
  • plik pdf

    "Discovery of novel MTA-cooperative PRMT5 inhibitors as a targeted therapeutic for MTAP deleted cancers"

    Pobierz
  • plik pdf

    "RVU120 SOL-021: An open-label, single agent, Phase I/II trial of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors"

    Pobierz